Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis

2003 ◽  
Vol 107 (6) ◽  
pp. 984-990 ◽  
Author(s):  
José-Juan Gaforio ◽  
María-José Serrano ◽  
Pedro Sanchez-Rovira ◽  
Antonio Sirvent ◽  
Miguel Delgado-Rodriguez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Cells ◽  
Peripheral Blood ◽  
Poor Prognosis ◽  
Breast Cancer Cells ◽  
Estrogen Receptor Status ◽  
Receptor Status

Prognostic relationship of SATB1 gene expression and estrogen receptor status in breast cancer cells.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 661-661
Author(s):  
L. Mavrova ◽  
T. Karn ◽  
L. Hanker ◽  
E. Ruckhäberle ◽  
V. Mueller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Estrogen Receptor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Estrogen Receptor Status ◽  
Receptor Status ◽  
Relationship Of

scholarly journals Estrogen Mediated-Activation of miR-191/425 Cluster Modulates Tumorigenicity of Breast Cancer Cells Depending on Estrogen Receptor Status

PLoS Genetics ◽  
2013 ◽  
Vol 9 (3) ◽  
pp. e1003311 ◽  
Author(s):  
Gianpiero Di Leva ◽  
Claudia Piovan ◽  
Pierluigi Gasparini ◽  
Apollinaire Ngankeu ◽  
Cristian Taccioli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Estrogen Receptor Status ◽  
Receptor Status

scholarly journals Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Bahriye Karakas ◽  
Yeliz Aka ◽  
Asli Giray ◽  
Sehime Gulsun Temel ◽  
Ufuk Acikbas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Cells ◽  
Endocrine Therapy ◽  
Breast Cancer Cells ◽  
Estrogen Receptor Status ◽  
High Rate ◽  
Estrogen Signaling ◽  
Receptor Subtypes ◽  
Receptor Status

AbstractBreast cancer is the most common cancer with a high rate of mortality and morbidity among women worldwide. Estrogen receptor status is an important prognostic factor and endocrine therapy is the choice of first-line treatment in ER-positive breast cancer. However, most tumors develop resistance to endocrine therapy. Here we demonstrate that BH3 profiling technology, in particular, dynamic BH3 profiling can predict the response to endocrine therapy agents as well as the development of acquired resistance in breast cancer cells independent of estrogen receptor status. Immunofluorescence analysis and subcellular fractionation experiments revealed distinct ER-α and ER-β subcellular localization patterns in breast cancer cells, including mitochondrial localization of both receptor subtypes. shRNA-mediated depletion of ER-β in breast cancer cells led to resistance to endocrine therapy agents and selective reconstitution of ER-β in mitochondria restored sensitivity. Notably, mitochondria-targeted ER-α did not restore sensitivity, even conferred further resistance to endocrine therapy agents. In addition, expressing mitochondria-targeted ER-β in breast cancer cells resulted in decreased mitochondrial respiration alongside increased total ROS and mitochondrial superoxide production. Furthermore, our data demonstrated that mitochondrial ER-β can be successfully targeted by the selective ER-β agonist Erteberel. Thus, our findings provide novel findings on mitochondrial estrogen signaling in breast cancer cells and suggest the implementation of the dynamic BH3 technique as a tool to predict acquired endocrine therapy resistance.

scholarly journals Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells.

2021 ◽  
Author(s):  
Ozgur Kutuk ◽  
Bahriye Karakas ◽  
Yeliz Aka ◽  
Asli Giray ◽  
Huveyda Basaga ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Cells ◽  
Endocrine Therapy ◽  
Breast Cancer Cells ◽  
Estrogen Receptor Status ◽  
High Rate ◽  
Estrogen Signaling ◽  
Receptor Subtypes ◽  
Receptor Status

Abstract Breast cancer is the most common cancer with a high rate of mortality and morbidity among women worldwide. Estrogen receptor status is an important prognostic factor and endocrine therapy is the choice of first-line treatment in ER-positive breast cancer. However, most tumors develop resistance to endocrine therapy. Here we demonstrate that BH3 profiling technology, in particular dynamic BH3 profiling can predict the response to endocrine therapy agents as well as development of acquired resistance in breast cancer cells independent of estrogen receptor status. Immunofluorescence analysis and subcellular fractionation experiments revealed distinct ER-α and ER-β subcellular localization patterns in breast cancer cells, including mitochondrial localization of both receptor subtypes. shRNA-mediated depletion of ER-β in breast cancer cells led to resistance to endocrine therapy agents and selective reconstitution of ER-β in mitochondria restored sensitivity. Notably, mitochondria-targeted ER-α did not restore sensitivity, even conferred further resistance to endocrine therapy agents. In addition, expressing mitochondria-targeted ER-β in breast cancer cells resulted in decreased mitochondrial respiration alongside increased total ROS and mitochondrial superoxide production. Furthermore, our data demonstrated that mitochondrial ER-β can be successfully targeted by the selective. ER-β agonist Erteberel. Thus, our findings provide novel findings on mitochondrial estrogen signaling in breast cancer cells and suggest the implementation of dynamic BH3 technique as a tool to predict acquired endocrine therapy resistance.

Sign in / Sign up

Export Citation Format

Share Document